Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors

Table 1

Arimidex tamoxifen alone or in combination trial. (a) Percent of patients with joint symptoms, and odds ratio (OR) for joint symptoms, in the population of patients without joint symptoms at study entry. (b) Significant predictive factors for joint symptoms from multivariate analysis in the population of patients without joint symptoms at study entry [20].

(a)

	Anastrozole 𝑁=2,698	Tamoxifen 𝑁=2,735	OR (95% CI)
Overall	35.2%	30.3%	1.25 (1.11–1.40)
Mild	19.2%	17.3%	1.14 (0.99–1.31)
Moderate	13.6%	10.8%	1.29 (1.09–1.53)
Severe	2.4%	2.2%	1.06 (0.73–1.54)

(b)

	OR (95% CI)	𝑃 Value
Anastrozole versus tamoxifen	1.26 (1.12–1.42)	<.0001
Previous hormone replacement  therapy versus none	1.53 (1.35–1.74)	<.0001
Chemotherapy versus none	1.24 (1.07–1.43)	.004
Hormone receptor status
Negative versus positive	0.78 (0.62–0.98)^a	.03
Unknown versus positive	0.76 (0.59–0.97)a	.028
Region
UK versus rest of world	1.20 (1.02–1.40)	.025
North America versus rest of world	2.09 (1.79–2.43)	<.0001
Body mass index >30	1.33 (1.14–1.55)	<.0001

a Negative predictor.
CI: confidence interval